Abstract
The present disclosure provides a single-chain T-cell modulatory polypeptide (TMP) that includes an NKG2 peptide, an HLA-E heavy chain polypeptide, a beta-2 microglobulin polypeptide, and an immunoglobulin Fc polypeptide. The TMP can also include an immunomodulatory polypeptide and/or a cancer-targeting polypeptide. The TMPs are useful in methods of modulating an immune response, which methods are also provided.
Full Text
What is claimed is:
The present disclosure provides a single-chain T-cell modulatory polypeptide (TMP) that includes an NKG2 peptide, an HLA-E heavy chain polypeptide, a beta-2 microglobulin polypeptide, and an immunoglobulin Fc polypeptide. The TMP can also include an immunomodulatory polypeptide and/or a cancer-targeting polypeptide. The TMPs are useful in methods of modulating an immune response, which methods are also provided.
Timeline
Filed
03/16/2026Published
07/02/2026Granted
Not AvailableIPC Codes(4)
C07K 14/705:Receptors; Cell surface antigens; Cell surface determinants
A61K 38/00:Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K 31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K 31/00; ergoline-based peptides A61K 31/48; containing macromolecular compounds having statistically distributed amino acid units A61K 31/74; medicinal preparations containing antigens or antibodies A61K 39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K 47/00)
C07K 14/55:IL-2